Abstract
Urine polyamine content is increased in patients with colorectal malignancy and may be a useful tumor marker in the management of these patients. Urinary excretion of putrescine and spermidine was measured preoperatively and in the first week postoperatively in nine patients with inflammatory bowel disease, eight with other benign colorectal disease, and 13 with colorectal cancer. Preoperative urine putrescine levels were elevated similarly in patients with inflammatory bowel disease and malignancy. Polyamine levels were increased in all three groups in the early postoperative period. Urinary polyamine excretion did not correlate with serum CEA levels, tumor volume, or stage of disease in patients with cancer. Because elevated levels of urinary polyamines are not specific for malignancy and do not correlate with other prognostic indicators, such measurements are unlikely to be useful in tumor detection and determining prognosis. Polyamine levels, however, may prove useful in monitoring response to therapy and detecting recurrences in individual patients.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Pegg AE, McCann PP. Polyamine metabolism and function. AMJ Physiol 1982;243:C212–21.
Heby O. Role of polyamines in the control of cell proliferation and differentiation. Differentiation 1981;19:1–20.
Yarrington JT, Sprinkle DJ, Loudy DE, Diekema KA, McCann PP, Gibson JP. Intestinal changes caused by DL-alpha-difluoromethylornithine (DFMO), an inhibitor of ornithine decarboxylase. Exp Mol Pathol 1983;39:300–16.
Kingsnorth AN, King WW, Diekema KA, McCann PP, Ross JS, Malt RA. Inhibition of ornithine decarboxylase with 2-difluoromethylornithine: reduced incidence of dimethylhydrazine-induced colon tumors in mice. Cancer Res 1983;43:2545–9.
Carachi R, Beeley JG. Polyamines in colorectal cancer: a clinical and experimental approach. J Clin Pathol 1983;36:508–10.
Depierre D, Jung A, Culebras J, Roth M. Polyamine excretion in the urine of cancer patients. J Clin Chem Clin Biochem 1983;21:35–7.
Desser H, Lutz D, Krieger O, Stierer M. Rapid detection of polyamines in the sera of patients with colorectal cancer by liquid ion-exchange chromatography. Oncology 1980;37:376–80.
Kingsnorth AN, Lumsden AB, Wallace HM. Polyamines in colorectal cancer. Br J Surg 1984;71:791–4.
Lipton A, Sheehan L, Harvey HA. Urinary polyamine levels in patients with gastrointestinal malignancy. Cancer 1975;36:2351–4.
Nishioka K, Romsdahl MM, McMurtrey MJ. Serum polyamine alterations in surgical patients with colorectal carcinoma. J Surg Oncol 1977;9:555–62.
Nishioka K, Romsdahl MM. Preliminary longitudinal studies of serum polyamines in patients with colorectal carcinoma. Cancer Lett 1977;3:197–202.
Waalkes TP, Gehrke CW, Tormey DC, et al. Urinary excretion of polyamines by patients with advanced malignancy. Cancer Chemother Rep 1975;59:1103–16.
Seidel ER, Haddox MK, Johnson LR. Polyamines in the response to intestinal obstruction. Am J Physiol 1984;246:G649–53.
Fletcher RH. Carcinoembryonic antigen. Ann Intern Med 1986;104:66–73.
Allan A, Bristol JB, Williamson RC. Crypt cell production rate in ulcerative proctocolitis: differential increments in remission and relapse. Gut 1985;26:999–1003.
Kingsnorth AN. The chemotherapeutic potential of polyamine antimetabolites. Ann R Coll Surg Engl 1986;68:76–81.
Luk GD, Baylin SB. Ornithine decarboxylase as a biologic marker in familial colonic polyposis. N Engl J Med 1984;311:80–3.
Author information
Authors and Affiliations
About this article
Cite this article
Thompson, J.S., Edney, J.A. & Laughlin, K. Urinary polyamines in colorectal cancer. Dis Colon Rectum 29, 873–877 (1986). https://doi.org/10.1007/BF02555367
Received:
Issue Date:
DOI: https://doi.org/10.1007/BF02555367